Pediatric allergy medications: review of currently available formulations

ABSTRACT

Background: Allergy affects about 50% of the pediatric population globally. Allergic rhinitis (AR), one form of allergy, causes considerable impairment in quality of life, including disruption of sleep and, in children, interference with school attendance and performance.

Scope: Traditional formulations and delivery systems – tablets, capsules, or intranasal sprays – successfully used by adults for treatment of AR may not be as easily administered in children. Liquid oral medications are more readily taken by children but contain sugars and excipients; they can also be inconvenient with less accurate dosing and are associated with dental caries and gastrointestinal upset.

Methodology: This review evaluated medications for treatment of AR currently available for pediatric patients and identified the attitudes of parents and health care professionals toward these medications. Guidelines from international organizations and governmental websites were reviewed for recommendations and product labeling requirements. A Medline search was conducted using the terms dyes, excipients, palatability, prescribing habits, sugar, among others.

Findings: In recent years, governmental regulatory agencies and professional organizations in Europe and the United States have recommended avoidance of sugar in pediatric medicines and required stricter labeling of their ingredients. Public awareness about the adverse effects of sugar and some excipients has also increased, and parents more frequently express the desire for safer and more convenient medicines for their children. In response, more sugar-free, dye-free liquid medicines and other formulations, such as granules, filmstrips, chewable tablets, fast-dissolving tablets, and drops, are becoming available for pediatric use.

Limitations: Data from well-designed trials conducted in children for the treatment of AR are lacking. In addition, the possibility of a social response bias may exist for parents and physicians about sugar and other ingredients in children's medications.

Conclusion: Treatment for AR is often long-term, particularly in persistent AR; therefore, safety, tolerability, convenience, and patient/parental acceptance are important considerations when deciding which medication to prescribe.

Key words: :

• Allergic rhinitis
• Antihistamines
• Liquid oral medications
• Orodispersible tablets
• Parental preferences
• Pediatric medications
• Syrups

Transparency

Declaration of funding

Financial support for this study was provided by Schering-Plough.

Declaration of financial/other relationships

G.S. is an advisory board member, lecturer and/or researcher for Schering-Plough, GlaxoSmithKline, MSD Pharmaceuticals PVT, Ltd, UCB, ALK and Groupo Uriach.

All peer reviewers receive honoraria from CMRO for their review work. The peer reviewers have disclosed that they have no relevant financial relationships.

Acknowledgment

Editorial assistance was provided by Patricia C. Abramo. This assistance was funded by Schering-Plough.